Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel Laboratory of Nano Delivery ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

More information: Mengting Jiang et al, Structural basis of the cysteinyl leukotriene receptor type 2 activation by LTD4, Proceedings of the National Academy of Sciences (2025). DOI: 10.1073/pnas.

Division of Cardiology, Department of Medicine, University of California, Los Angeles (H.M.S., K.E.J., T.Q.d.A.V., E.J.T.). Division of Cardiology, Department of ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—known as GLP-1 receptor agonists (GLP ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that ...

AM PEF: Weakly mean morning peak expiratory flow; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; LTRA: Leukotriene-receptor antagonist. Chronic overproduction of cysteinyl ...

Despite the wealth of data demonstrating their physiological benefits, the putative high-affinity receptor that mediates these effects is yet to be identified. The recent report that the sphingosine-1 ...